ATE401348T1 - Immunokonjugate mit hoher bindungsaffinität - Google Patents

Immunokonjugate mit hoher bindungsaffinität

Info

Publication number
ATE401348T1
ATE401348T1 AT00937925T AT00937925T ATE401348T1 AT E401348 T1 ATE401348 T1 AT E401348T1 AT 00937925 T AT00937925 T AT 00937925T AT 00937925 T AT00937925 T AT 00937925T AT E401348 T1 ATE401348 T1 AT E401348T1
Authority
AT
Austria
Prior art keywords
mesothelin
antibodies
immunoconjugates
present
cancers
Prior art date
Application number
AT00937925T
Other languages
English (en)
Inventor
Ira Pastan
Partha Chowdhury
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE401348T1 publication Critical patent/ATE401348T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00937925T 1999-05-27 2000-05-26 Immunokonjugate mit hoher bindungsaffinität ATE401348T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16007199P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
ATE401348T1 true ATE401348T1 (de) 2008-08-15

Family

ID=22575396

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00937925T ATE401348T1 (de) 1999-05-27 2000-05-26 Immunokonjugate mit hoher bindungsaffinität

Country Status (10)

Country Link
US (1) US7081518B1 (de)
EP (2) EP1180123B1 (de)
JP (3) JP5683766B2 (de)
AT (1) ATE401348T1 (de)
AU (1) AU5303700A (de)
CA (1) CA2374398C (de)
DE (1) DE60039510D1 (de)
DK (1) DK1180123T3 (de)
MX (1) MXPA01011950A (de)
WO (1) WO2000073346A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6809184B1 (en) * 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1532162B1 (de) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore
AU2003259109A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
ES2343965T3 (es) 2003-11-25 2010-08-13 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anticuerpos anti-cd22 e inmunocongujados mutados.
EP1716179A2 (de) * 2004-02-12 2006-11-02 Morphotek, Inc. Monoklonaler antikörper spezifisch für den folatrezeptor alpha
EP2322560B1 (de) * 2005-03-10 2013-09-04 Morphotek, Inc. Anti-Mesothelin-Antikörper
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
WO2006124641A2 (en) * 2005-05-12 2006-11-23 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Anti-mesothelin antibodies useful for immunological assays
WO2007016150A2 (en) * 2005-07-29 2007-02-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Mutated pseudomonas exotoxins with reduced antigenicity
NZ579010A (en) 2007-02-20 2012-03-30 Anaptysbio Inc Somatic hypermutation systems
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
EP2197903B9 (de) 2007-09-04 2015-04-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Deletionen in der domäne ii von pseudomonas-exotoxin, die die nichtspezifische toxizität vermindern
SI2195017T1 (sl) 2007-10-01 2015-01-30 Bristol-Myers Squibb Company Človeška protitelesa, ki vežejo mezotelin in njihova uporaba
AU2009228361A1 (en) 2008-03-27 2009-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human anti-mesothelin monoclonal antibodies
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
CA2773665C (en) 2009-09-11 2018-02-20 Ira H. Pastan Improved pseudomonas exotoxin a with reduced immunogenicity
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011100455A1 (en) 2010-02-12 2011-08-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of antibody responses to foreign proteins
ES2611479T3 (es) 2010-06-16 2017-05-09 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Anticuerpos contra endoplasmina y su uso
PE20170917A1 (es) 2010-12-20 2017-07-12 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
WO2012145469A1 (en) 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
MX2013012905A (es) 2011-05-06 2014-04-25 Us Gov Health & Human Serv Inmunotoxina recombinante dirigida a la mesotelina.
KR20140033391A (ko) 2011-06-09 2014-03-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 면역원성이 보다 낮은 t 세포 및/또는 b 세포 에피토프를 갖는 슈도모나스 외독소 a
EP3301110A1 (de) 2011-09-16 2018-04-04 The USA, as represented by The Secretary, Department of Health and Human Services Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen
CA2868121C (en) 2012-03-23 2021-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
WO2014031476A1 (en) 2012-08-21 2014-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
WO2014052064A1 (en) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
US9890369B2 (en) 2013-06-20 2018-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
CA2926215A1 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
GB201500464D0 (en) 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
GB201616699D0 (en) 2016-09-30 2016-11-16 Mab Designs Ltd Antibodies
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
EP3638295A1 (de) 2017-06-13 2020-04-22 TCR2 Therapeutics Inc. Zusammensetzungen und verfahren zur tcr-reprogrammierung mithilfe von fusionsproteinen
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019055955A1 (en) 2017-09-18 2019-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN
JP6339283B1 (ja) * 2017-10-31 2018-06-06 国立大学法人 岡山大学 Ｄｎａ、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体
CN111683962B (zh) 2017-11-10 2025-05-16 美国政府(由卫生和人类服务部的部长所代表) 靶向肿瘤抗原的嵌合抗原受体
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
PL3820569T3 (pl) 2018-07-12 2025-07-14 Invox Pharma Limited Cząsteczki przeciwciał, które wiążą PD-L1 oraz CD137
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
MX2021002225A (es) 2018-08-30 2021-07-16 Tcr2 Therapeutics Inc Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
WO2020084298A1 (en) * 2018-10-22 2020-04-30 Fusion Antibodies Plc Antibody library and method
CN109517070A (zh) * 2018-11-07 2019-03-26 南京卡提医学科技有限公司 嵌合抗原受体DAP12-T2A-CD8α-MSLN scFv-TREM1及其用途
AU2020206308B2 (en) 2019-01-08 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
CN116209679A (zh) * 2020-06-05 2023-06-02 财团法人生物技术开发中心 含有抗间皮素抗体的抗体-药物共轭物及其用途
IL298921A (en) 2020-07-10 2023-02-01 Hoffmann La Roche Antibodies that bind to cancer cells and direct radionuclides to said cells
US20240009239A1 (en) * 2020-11-04 2024-01-11 Fred Hutchinson Cancer Center Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy
US20240173442A1 (en) 2021-01-13 2024-05-30 Hoffmann-La Roche Inc. Combination therapy
IL311570A (en) 2021-10-14 2024-05-01 Arsenal Biosciences Inc Immune cells with common expression chain and logic gate systems
EP4448566A1 (de) 2021-12-17 2024-10-23 The United States of America, as represented by the Secretary, Department of Health and Human Services Anti-mesothelin-polypeptide, proteine und chimäre antigenrezeptoren
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
WO2025240496A1 (en) 2024-05-14 2025-11-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060165A (en) 1962-10-23 Preparation of toxic ricin
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
CA2093928C (en) 1990-10-12 2000-02-29 Mark C. Willingham Monoclonal antibodies for detection and treatment of cancer
JP3328341B2 (ja) 1991-12-27 2002-09-24 中外製薬株式会社 新規な巨核球増幅因子
IL107366A (en) 1992-10-23 2003-03-12 Chugai Pharmaceutical Co Ltd Genes coding for megakaryocyte potentiator
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
DE69638269D1 (de) * 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
JP2000505787A (ja) 1996-01-05 2000-05-16 アメリカ合衆国 中皮抗原及びそれを標的化するための方法及びキット
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US6809184B1 (en) 1997-12-01 2004-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use

Also Published As

Publication number Publication date
DE60039510D1 (de) 2008-08-28
JP2003502030A (ja) 2003-01-21
EP1180123A1 (de) 2002-02-20
WO2000073346A1 (en) 2000-12-07
EP2011801A1 (de) 2009-01-07
EP1180123B1 (de) 2008-07-16
AU5303700A (en) 2000-12-18
US7081518B1 (en) 2006-07-25
MXPA01011950A (es) 2002-05-06
JP2014050409A (ja) 2014-03-20
DK1180123T3 (da) 2008-10-13
CA2374398C (en) 2011-03-15
CA2374398A1 (en) 2000-12-07
JP5683766B2 (ja) 2015-03-11
JP2012050464A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
DE60039510D1 (de) Immunokonjugate mit hoher bindungsaffinität
IL135775A0 (en) Antibodies and immunoconjugates having high binding affinity for mesothelin
DE69937899D1 (de) Antikörper-serumprotein hybride
DE69632401D1 (de) Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
EE04752B1 (et) Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
DE60134962D1 (de) Anti-ccr4 antikörper und fragmente davon
HUT70471A (en) Antitumor imunoconjugates, method for producing them, and pharmaceutical compositions containing the conjugates
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
EP1090924A4 (de) Von cyclophilin b abstammende tumorantigen-peptide
EA200100224A1 (ru) Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
HUP0102992A3 (en) Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis
JP2021518397A5 (de)
PL366575A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka jajnika
DE69631686D1 (de) Entwurf hormonartiger antikörper mit agonistischen und antagonistischen eigenschaften
ES2090052T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y uso.
FI950062A0 (fi) Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
RU92016354A (ru) Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата
ATE464383T1 (de) Tumor antigen
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
NZ326436A (en) Ligand directed enzyme prodrug therapy for tumours using ligands that recognise and bind tumour receptors
DE59712259D1 (de) E-Cadherin-Mutationen als Grundlage zur Diagnostik und Therapie humaner maligner Tumoren
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
Bidard et al. Trends in cancer-targeted antibody–drug conjugates
DE69724761D1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
FI914924A0 (fi) Monoklonal antikropp foer differentiering av fjaellande cell karcinomantigener och foerfarande foer anvaendning daerav.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties